ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) shares hit a new 52-week low during trading on Friday . The stock traded as low as $2.45 and last traded at $2.46, with a volume of 1037833 shares traded. The stock had previously closed at $2.56.
Analyst Upgrades and Downgrades
IBRX has been the subject of several recent research reports. EF Hutton Acquisition Co. I raised ImmunityBio to a "strong-buy" rating in a research note on Wednesday, October 23rd. BTIG Research assumed coverage on shares of ImmunityBio in a research note on Friday. They set a "buy" rating and a $6.00 target price for the company. Finally, D. Boral Capital reiterated a "buy" rating and set a $30.00 price target on shares of ImmunityBio in a report on Monday.
Read Our Latest Analysis on IBRX
ImmunityBio Trading Down 5.5 %
The firm's 50-day moving average price is $3.96 and its 200 day moving average price is $4.37. The company has a market cap of $1.69 billion, a price-to-earnings ratio of -2.63 and a beta of 0.86.
Institutional Investors Weigh In On ImmunityBio
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Captrust Financial Advisors acquired a new position in ImmunityBio during the third quarter worth $41,000. Algert Global LLC acquired a new stake in shares of ImmunityBio in the 2nd quarter worth about $86,000. Virtu Financial LLC acquired a new stake in shares of ImmunityBio in the 3rd quarter worth about $51,000. Dimensional Fund Advisors LP bought a new position in ImmunityBio in the 2nd quarter valued at about $105,000. Finally, Mercer Global Advisors Inc. ADV acquired a new position in ImmunityBio during the 2nd quarter valued at about $126,000. 8.58% of the stock is owned by institutional investors.
ImmunityBio Company Profile
(
Get Free Report)
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
See Also
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
